Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSage Group Regulatory News (SGE)

Share Price Information for Sage Group (SGE)

Share Price is delayed by 15 minutes
Get Live Data
818.60    16.60 (2.07%)
Bid:
818.40
Ask:
819.00
Spread: 0.60 (0.073%)
Market Cap: £7.38b
SGE Live PriceLast checked at - London Stock Exchange

Intraday Sage Group Share Chart

Stabilisation Notice

1 Feb 2022 10:26

RNS Number : 3215A
J.P. Morgan Securities PLC.
01 February 2022
 

1st of February 2022

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

The Sage Group plc

Pre-stabilisation Period Announcement

J.P. Morgan Securities plc, (contact: Marc Lewell +33 1 40 15 44 39) hereby gives notice, as Stabilisation Coordinator, that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Delegated Regulation EU/xxx/2016 under the Market Abuse Regulation (EU/596/2016).

The securities:

Issuer:

The Sage Group plc

Guarantor (if any):

Sage Treasury Company Limited

Aggregate nominal amount:

GBP bmk

Description:

GBP 12-year Senior, Unsecured, RegS Bearer, NGN, TEFRA D rules apply (no communications with or into the U.S.)

Listing: London Stock Exchange

Offer price:

TBD

Other offer terms:

Denoms: £100k + 1k

Stabilisation:

Stabilisation Manager(s):

J.P. Morgan Securities plc (Stabilisation coordinator)

NatWest Markets (Stabilisation Manager(s))

HSBC ( (Stabilisation Manager(s))

BofA ( (Stabilisation Manager(s))

 

Stabilisation period expected to start on:

1st February 2022

Stabilisation period expected to end no later than:

1st March 2022

Existence, maximum size and conditions of use of overallotment facility:

The Stabilisation Manager(s) may over-allot the securities in an amount not exceeding 5% of the aggregate nominal amount stated above.

Stabilisation trading venue:

Over the counter, TBC

 

In connection with the offer of the above securities, the Stabilising Manager(s), or persons acting on behalf of the Stabilising Manager(s) may over-allot the securities, provided that the aggregate principal amount of the securities allotted does not exceed 105 percent of the aggregate principal amount of the securities, or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time, but it must end no later than the earlier of 30 days after the issue date of the securities and 60 days after the date of allotment of the securities.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within Article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that in that Member State

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAEAEAFEAAAEFA
Date   Source Headline
23rd Dec 20251:15 pmRNSHolding(s) in Company
22nd Dec 20256:25 pmRNSTransaction in Own Shares
22nd Dec 20256:25 pmRNSTransaction in Own Shares
19th Dec 20256:25 pmRNSTransaction in Own Shares
19th Dec 20256:25 pmRNSTransaction in Own Shares
18th Dec 20256:25 pmRNSTransaction in Own Shares
18th Dec 20256:25 pmRNSTransaction in Own Shares
17th Dec 20256:25 pmRNSTransaction in Own Shares
16th Dec 20256:25 pmRNSTransaction in Own Shares
12th Dec 20256:25 pmRNSTransaction in Own Shares
11th Dec 20256:25 pmRNSTransaction in Own Shares
11th Dec 20255:45 pmRNSDirector/PDMR Shareholding
11th Dec 20255:45 pmRNSDirector/PDMR Shareholding
10th Dec 20256:25 pmRNSTransaction in Own Shares
9th Dec 20256:25 pmRNSTransaction in Own Shares
8th Dec 20256:25 pmRNSTransaction in Own Shares
8th Dec 202512:00 pmRNSBlock listing Interim Review
5th Dec 20256:25 pmRNSTransaction in Own Shares
5th Dec 20254:31 pmRNSDirector/PDMR Shareholding
4th Dec 20256:25 pmRNSTransaction in Own Shares
4th Dec 20256:15 pmRNSDirector/PDMR Shareholding
4th Dec 202511:00 amRNSNotice of AGM
3rd Dec 20255:01 pmRNSDirector/PDMR Shareholding
2nd Dec 202510:45 amRNSAnnual Financial Report
28th Nov 20256:25 pmRNSTransaction in Own Shares
28th Nov 20254:30 pmRNSTotal Voting Rights
27th Nov 20256:25 pmRNSTransaction in Own Shares
25th Nov 20256:25 pmRNSTransaction in Own Shares
24th Nov 20256:25 pmRNSTransaction in Own Shares
20th Nov 20256:25 pmRNSTransaction in Own Shares
19th Nov 20257:00 amRNSSHARE BUYBACK PROGRAMME
19th Nov 20257:00 amRNSResults for the year ended 30 September 2025
31st Oct 20254:00 pmRNSTotal Voting Rights
3rd Oct 20259:41 amRNSHolding(s) in Company
30th Sep 20253:50 pmRNSTotal Voting Rights
15th Sep 202510:00 amRNSDirector Declaration
29th Aug 20254:50 pmRNSTotal Voting Rights
20th Aug 20252:10 pmRNSDirector/PDMR Shareholding
4th Aug 20255:40 pmRNSDirector/PDMR Shareholding
1st Aug 20253:10 pmRNSDirector/PDMR Shareholding
31st Jul 20255:00 pmRNSTotal Voting Rights
31st Jul 20251:55 pmRNSDirector/PDMR Shareholding
30th Jul 20255:54 pmRNSTransaction in Own Shares
30th Jul 20257:00 amRNSTrading update for nine months ended 30 June 2025
29th Jul 20256:17 pmRNSTransaction in Own Shares
28th Jul 20256:02 pmRNSTransaction in Own Shares
25th Jul 20255:39 pmRNSTransaction in Own Shares
24th Jul 20255:54 pmRNSTransaction in Own Shares
23rd Jul 20255:57 pmRNSTransaction in Own Shares
22nd Jul 20255:56 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.